Glucose Metabolism Disorders  >>  Remozen (remogliflozin etabonate)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Remozen (remogliflozin etabonate) / Islet Sci
NCT00291356 / 2005-002978-30: GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients

Completed
2
45
US, Europe
GSK189075 oral tablets, GW869682 oral tablets
GlaxoSmithKline
Diabetes Mellitus, Type 2, Non-Insulin-Dependent Diabetes Mellitus
05/06
05/06
NCT00500331 / 2006-004694-97: Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)

Completed
2
334
US, Europe, RoW
GSK189075, pioglitazone, Placebo
GlaxoSmithKline
Diabetes Mellitus, Type 2
02/08
02/08
NCT00495469 / 2007-001463-29: Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive

Completed
2
250
US, Canada, Europe, RoW
GSK189075, Placebo
GlaxoSmithKline
Diabetes Mellitus, Type 2
06/08
06/08
NCT00575159: A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes Mellitus

Completed
2
10
US
GSK189075, placebo
GlaxoSmithKline
Diabetes Mellitus, Type 1
12/08
12/08
BRID, NCT02537470: Safety and Efficacy of Biphasic Remogliflozin Etabonate in the Treatment of Type 2 Diabetes

Completed
2
191
US
Biphasic Remogliflozin Etabonate, Placebo
BHV Pharma, Integrium
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
08/16
08/16

Download Options